Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronaviruses

11 Jan 2022

Abstract excerpt

The COVID-19 pandemic caused by SARS-CoV-2 has been socially and economically devastating. Despite an unprecedented research effort and available vaccines, effective therapeutics are still missing to limit severe disease and mortality. Using high-throughput screening, we identify acriflavine (ACF) as a potent papain-like protease (PL pro ) inhibitor. NMR titrations and a co-crystal structure confirm that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19 Clinical Research Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to SARS-CoV-2 detection and testing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35021060
DOI: 10.1016/j.chembiol.2021.11.006

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acriflavine, a clinically approved drug, inhibits SARS-CoV-2 and other betacoronavirusesPMID 35021060Read ↗

Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19Semantic proximity Read ↗

Massive Virtual screening and evaluation of small molecule inhibitors of the Papain-like protease of SARS-CoV-2Semantic proximity Read ↗

Massive Virtual screening and evaluation of small molecule inhibitors of the Papain-like protease of SARS-CoV-2Semantic proximity Read ↗

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors.Semantic proximity Read ↗

Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitorsSemantic proximity Read ↗

Genetic Algorithm-Based Docking of Potent Inhibitors Against SARS-CoV-2 Main Protease: A Comparison Between Natural Products and Synthetic Drugs.Semantic proximity Read ↗

Discovery of novel papain-like protease inhibitors for potential treatment of COVID-19Semantic proximity Read ↗

Identification of naturally occurring drug-resistant mutations of SARS-CoV-2 papain-like proteaseSemantic proximity Read ↗

Discovery of SARS-CoV-2 papain-like protease (PL <sup>pro</sup> ) inhibitors with efficacy in a murine infection modelSemantic proximity Read ↗

Repurposing screen identifies novel candidates for broad-spectrum coronavirus antivirals and druggable host targetsSemantic proximity Read ↗

Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19Semantic proximity Read ↗

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus M Pro inhibitors with potent in vivo efficacySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.